이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Xencor 관리

관리 기준 확인 2/4

Xencor's CEO는 Bassil Dahiyat, Aug1997 에 임명되었습니다 의 임기는 27.08 년입니다. 총 연간 보상은 $ 7.97M, 8.8% 로 구성됩니다. 8.8% 급여 및 91.2% 보너스(회사 주식 및 옵션 포함). 는 $ 4.30M 가치에 해당하는 회사 주식의 0.4% 직접 소유합니다. 4.30M. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 7.4 년입니다.

주요 정보

Bassil Dahiyat

최고 경영자

US$8.0m

총 보상

CEO 급여 비율	8.8%
CEO 임기	27.1yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	7.4yrs

최근 관리 업데이트

Recent updates

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27

Xencor: Standing Out With XmAb Technology

Feb 03

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Jan 05

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Nov 13

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Nov 10

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18

Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts

Aug 06

CEO 보상 분석

Bassil Dahiyat 의 보수는 Xencor 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$133m
Dec 31 2023	US$8m	US$700k	-US$126m
Sep 30 2023	n/a	n/a	-US$119m
Jun 30 2023	n/a	n/a	-US$128m
Mar 31 2023	n/a	n/a	-US$140m
Dec 31 2022	US$8m	US$670k	-US$55m
Sep 30 2022	n/a	n/a	US$30m
Jun 30 2022	n/a	n/a	US$22m
Mar 31 2022	n/a	n/a	US$109m
Dec 31 2021	US$5m	US$625k	US$83m
Sep 30 2021	n/a	n/a	-US$4m
Jun 30 2021	n/a	n/a	US$24m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$4m	US$600k	-US$69m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$80m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$4m	US$567k	US$27m
Sep 30 2019	n/a	n/a	US$36m
Jun 30 2019	n/a	n/a	US$49m
Mar 31 2019	n/a	n/a	US$39m
Dec 31 2018	US$4m	US$550k	-US$70m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$71m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$5m	US$525k	-US$38m

보상 대 시장: Bassil 의 총 보상 ($USD 7.97M )은 US 시장( $USD 3.30M ).

보상과 수익: 회사가 수익성이 없는 동안 Bassil 의 보상이 증가했습니다.

CEO

Bassil Dahiyat (54 yo)

27.1yrs

테뉴어

US$7,965,955

보상

Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...

리더십 팀

이름	위치	테뉴어	보상	소유권
Bassil Dahiyat	Co-Founder	27.1yrs	US$7.97m	0.35% $ 5.0m
John Desjarlais	Executive VP of Research & Chief Scientific Officer	10.2yrs	US$3.21m	0.22% $ 3.1m
Celia Eckert	Senior VP	5yrs	US$2.02m	0.027% $ 379.5k
Nancy Valente	Executive VP & Chief Development Officer	1.3yrs	US$5.35m	0.013% $ 188.0k
Bart Cornelissen	Senior VP & CFO	less than a year	데이터 없음	데이터 없음
Charles Liles	Associate Director and Head of Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음
Jennifer Sandoz	Senior VIce President of Human Resources	3.1yrs	데이터 없음	데이터 없음
Jeremy Grunstein	Senior Vice President of Business Development	2.7yrs	데이터 없음	데이터 없음
Kirk Rosemark	Senior Vice President of Regulatory Affairs & Quality Assurance	2.7yrs	데이터 없음	데이터 없음
Eric Kowack	Senior Vice President of Program Leadership & Alliance Management	1.7yrs	데이터 없음	데이터 없음
Dane Leone	Senior VP of Corporate Strategy	less than a year	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: XNCR 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bassil Dahiyat	Co-Founder	27.1yrs	US$7.97m	0.35% $ 5.0m
Richard Ranieri	Independent Director	6.8yrs	US$347.02k	0% $ 0
Alan Montgomery	lead Independent Director	9.5yrs	US$384.19k	0% $ 0
Kevin Gorman	Independent Director	7.4yrs	US$342.50k	0.000080% $ 1.1k
Jeffrey Ravetch	Member of Scientific Advisory Board	15.3yrs	데이터 없음	데이터 없음
Ellen Feigal	Independent Director	5.8yrs	US$348.00k	0% $ 0
Kurt Gustafson	Independent Director	10.2yrs	US$346.50k	0.0014% $ 20.2k
Dagmar Rosa-Bjorkeson	Independent Director	4.8yrs	US$346.25k	0% $ 0
Barbara Klencke	Independent Director	less than a year	US$467.35k	데이터 없음

7.4yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: XNCR 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.

Xencor 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Insider notifies of intention to sell stock

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Recent updates

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor: Vudalimab Development Along With Hidden Gem Candidate

Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up

Xencor, Inc. has filed a Follow-on Equity Offering.

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)

Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?

Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S

Consensus revenue estimates fall by 18%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Xencor: Standing Out With XmAb Technology

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Price target decreased by 7.0% to US$40.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Consensus revenue estimates increase by 19%

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Co-Founder notifies of intention to sell stock

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Consensus EPS estimates fall by 20%

Insufficient new directors

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder recently sold US$183k worth of stock

Consensus revenue estimates decrease by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improves as stock rises 15%

Senior VP & Chief Medical Officer recently sold US$101k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Price target decreased to US$50.13

Consensus revenue estimates increase by 40%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Co-Founder recently sold US$72k worth of stock